| Total | Patients with composite endpoint | Patients without composite endpoint | P-value |
---|---|---|---|---|
Demographics | ||||
 Total, % | 975 | 72 (7.4%) | 903 (92.6%) |  |
 Female, % | 29.2% (285/975) | 33.3% (24/72) | 28.9% (261/903) | 0.45 |
 Age, (years) | 62 (52–73) | 68 (53–78) | 62 (52–72) | < 0.05 |
Clinical presentation | ||||
 BMI, kg/m2 | 27 (25–30) | 26 (25–29) | 28 (25–30) | < 0.03 |
 Adiposity (BMI > 30), % | 24.0% (220/916) | 12.7% (8/63) | 24.9% (212/853) | < 0.05 |
Medical history | ||||
 Previous MI, % | 14.0% (135/961) | 24.3% (17/70) | 13.2% (118/891) | < 0.05 |
 Previous PCI, % | 12.5% (120/960) | 14.3% (10/70) | 12.4% (110/890) | 0.64 |
 Previous CABG, % | 3.3% (32/962) | 7.1% (5/70) | 3.0% (27/892) | 0.06 |
 Previous stroke, % | 3.0% (29/963) | 4.3% (3/70) | 2.9% (26/893) | 0.52 |
 Hypertension, % | 71.4% (688/964) | 70.4% (50/71) | 71.4% (638/893) | 0.85 |
 Hypercholesterolemia, % | 74.9% (719/960) | 59.7% (43/72) | 76.1% (676/888) | < 0.01 |
 Diabetes mellitus, % | 24.0% (234/975) | 29.1% (21/72) | 23.5% (213/903) | 0.27 |
 Current smoker, % | 46.9% (449/958) | 31.9% (22/69) | 48.0% (427/889) | < 0.01 |
 PAD, % | 5.7% (54/946) | 13.0% (9/69) | 5.1% (45/877) | < 0.01 |
 Aspirin on admission, % | 23.7% (221/957) | 37.1% (26/70) | 22.0% (195/887) | < 0.01 |
Laboratory on admission | ||||
 Potassium, mmol/L | 4.0 (3.7–4.3) | 4.2 (3.8–4.7) | 4.0 (3.7–4.3) | < 0.05 |
 Creatinine, mg/dl | 0.9 (0.8–1.1) | 1.1 (0.9–1.4) | 0.9 (0.8–1.1) | < 0.0001 |
 Elevated CRP (≥5×), % | 10.3% (76/741) | 14.3% (8/56) | 9.9% (68/685) | 0.30 |
 WBC > 10.000 μl, % | 57.0% (547/960) | 72.0% (52/72) | 55.7% (495/885) | < 0.01 |
 HbA1c, % | 8.4 ± 7.5 | 10.4 ± 13.8 | 8.1 ± 6.4 | 0.9 |
ECG on admission | ||||
 anterior STEMI, % | 39.5% (383/970) | 55.6% (40/72) | 38.5% (343/891) | < 0.05 |
 AF, % | 4.4% (42/968) | 10.3% (7/71) | 3.9% (35/890) | < 0.01 |
 LBBB, % | 1.8% (17/965) | 5.5% (4/72) | 1.5% (13/888) | < 0.05 |
 AV block, % | 3.9% (38/968) | 4.1% (3/72) | 3.9% (35/820) | 0.97 |
Coronary angiogram and intervention | ||||
 Three-vessel disease, % | 27.3% (266/975) | 31.9% (23/72) | 26.9% (243/903) | 0.36 |
 Time to reperfusion < 4 h, % | 89.3% (868/972) | 92.4% (67/72) | 89.6% (795/893) | 0.35 |
 Coronary thrombus, % | 19.2% (187/973) | 33.3% (24/72) | 18.2% (163/894) | < 0.01 |
 Stent implantation, % | 98.7% (956/969) | 97.2% (70/72) | 99.5% (886/890) | < 0.05 |
 GPIIa-IIIb antagonist, % | 2.9% (28/965) | 6.9% (5/72) | 2.6% (23/887) | 0.05 |
 Bivalirudin, % | 15.0% (145/968) | 20.3% (15/72) | 14.5% (130/889) | 0.17 |
Clinical course | ||||
 CCU stay, h | 46 (32–54) | 49 (20–169) | 46 (33–52) | 0.17 |
 Routine hospital ward stay, h | 150 (120–193) | 170 (105–200) | 150 (120–193) | 0.60 |
 Telemetric monitoring, h | 47 (33–66) | 50 (13–192) | 47 (33–58) | 0.26 |
 Use of vasopressors, % | 12.5% (122/975) | 83.5% (60/72) | 6.9% (62/896) | < 0.0001 |
 Maximum troponin value, U/L | 3.4 (1.5–6.4) | 5.9 (1.7–14.1) | 3.3 (1.5–6.1) | < 0.01 |
 Maximum CK value, mg/dl | 1413 (549–2822) | 2178 (609–4513) | 1351 (545–2706) | < 0.01 |
Clinical outcome | ||||
 EF < 30%, % | 9.3% (80/857) | 43.4% (23/53) | 7.1% (57/804) | < 0.0001 |
 Death | 6.5% (63/974) | 72.2% (52/72) | 1.2% (11/896) | < 0.0001 |
 Cardiac death, % of total | 88.9% (56/63) | 96.2% (50/52) | 54.5% (6/11) | < 0.001 |